Ser231
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser231  -  C/EBP-beta (human)

Site Information
LsTSSsssPPGtPSP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455886
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 )
Disease tissue studied:
bone cancer ( 11 ) , osteosarcoma ( 11 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , non-small cell lung cancer ( 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , non-small cell lung adenocarcinoma ( 1 , 4 , 5 , 6 , 7 , 8 , 10 ) , non-small cell large cell lung carcinoma ( 4 , 6 ) , small-cell lung cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 12 ) , Cal-12T (pulmonary) ( 8 ) , Calu-3 (pulmonary) ( 5 ) , DMS153 (pulmonary) ( 7 ) , DMS53 (pulmonary) ( 3 ) , DMS79 (pulmonary) ( 2 ) , HCC44 (pulmonary) ( 8 ) , HCC78 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 5 ) , lung ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , NCI-H128 (pulmonary) ( 2 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1417 (pulmonary) ( 2 ) , NCI-H1437 (pulmonary) ( 7 , 8 ) , NCI-H1650 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 8 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1781 (pulmonary) ( 6 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H1975 (pulmonary) ( 5 ) , NCI-H2073 (pulmonary) ( 7 ) , NCI-H209 (pulmonary) ( 2 , 7 ) , NCI-H2106 (pulmonary) ( 5 ) , NCI-H2228 (pulmonary) ( 6 , 10 ) , NCI-H2405 (pulmonary) ( 8 ) , NCI-H3122 (pulmonary) ( 6 , 9 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H446 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H524 (pulmonary) ( 2 ) , NCI-H526 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 6 ) , NCI-H69 (pulmonary) ( 3 ) , NCI-H82 (pulmonary) ( 3 ) , NCI-H838 (pulmonary) ( 7 ) , PC9 (pulmonary) ( 1 ) , U2OS (bone cell) ( 11 )

References 

1

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

10

Rikova K (2013) CST Curation Set: 18458; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

11

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

12

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info